What is the difference between frailty and just being old?

Not all older adults are frail — many people in their eighties and nineties maintain robust physical function and resilience. Frailty is a clinical syndrome, not a synonym for ageing. It is defined by measurable criteria: unintentional weight loss, exhaustion, weakness (low grip strength), slowness (reduced walking speed), and low physical activity. A person who meets three or more of these criteria is frail; those with one or two are pre-frail and at the highest-yield intervention point. The distinction matters practically because frail patients decompensate from minor stressors that healthy older adults would tolerate easily — for example, a urinary tract infection causing acute confusion and a fall, rather than just a few days of discomfort. Identifying frailty early allows targeted intervention before this point is reached.

What is the Clinical Frailty Scale and how is it used?

The Clinical Frailty Scale (CFS), developed by Rockwood and colleagues and published in CMAJ 2005, is a nine-point pictorial scale ranging from 1 (very fit) to 9 (terminally ill). It is completed by clinical impression — no equipment is needed. A score of 5 or above indicates mild-to-moderate frailty and is a clinical inflection point for proactive action: medication review, allied health referral, advance care planning discussion, and monitoring for deconditioning. The CFS is the most practical general-practice frailty screening tool and is embedded in the annual 75+ Health Assessment (MBS item 705). It is also used for surgical risk stratification and decisions about the intensity of hospital-based care. For Aboriginal and Torres Strait Islander patients, frailty appears earlier — apply 75+ assessment thresholds from age 55.

What is sarcopenia and how is it diagnosed?

Sarcopenia is the progressive, generalised loss of skeletal muscle strength and mass that occurs with ageing, accelerated by inactivity, malnutrition, and chronic disease. The EWGSOP2 consensus (Cruz-Jentoft, Age & Ageing 2019) defines it in stages: probable sarcopenia when grip strength is below 27 kg in men or 16 kg in women (or chair-rise time exceeds 15 seconds for five stands); confirmed sarcopenia when low muscle quantity is also found on DXA or bioimpedance; and severe sarcopenia when physical performance is also reduced (walking speed below 0.8 m/s, SPPB score ≤8, or Timed Up and Go above 20 seconds). In Australian general practice, a grip strength dynamometer and chair-rise test are the most accessible bedside assessments. DXA adds body composition data — useful when osteoporosis assessment is also indicated.

What exercises are most effective for frailty and sarcopenia?

Progressive resistance training (PRT) — working against gradually increasing loads — is the single most evidence-supported intervention. A Cochrane review (Liu and Latham 2009) across 121 trials found PRT improves strength, gait speed, chair-rise performance, and functional capacity in older adults. The LIFE trial (Pahor et al., JAMA 2014) found that a combined programme of resistance, balance, and aerobic exercise reduced major mobility disability in pre-frail and frail community-dwelling older adults. The practical recommendation is two to three sessions per week targeting major lower-limb muscle groups (squat, leg press, knee extension, calf raise) plus upper limb, with intensity progressed over eight to twelve weeks. Exercise physiologist referral under GPCCMP (MBS item 10953) provides supervised prescription. Tai chi adds balance benefit and fall risk reduction. A short walk is not enough — intensity and progressive loading are essential for muscle preservation.

How much protein do older adults need to preserve muscle?

More than previously recognised. The PROT-AGE consensus (Bauer et al., JAMDA 2013) recommends 1.0–1.2 g of protein per kilogram of body weight per day for healthy older adults, and 1.2–1.5 g/kg/day during recovery from illness, surgery, or acute deconditioning. Distribution across meals matters — 25–30 g of protein per meal optimises muscle protein synthesis by providing a sufficient leucine stimulus. A common failure is the 'tea and toast' dietary pattern, where most calories come from carbohydrates and total daily protein is well below requirements. Good protein sources include meat, fish, eggs, dairy, legumes, and soy. Protein supplements (whey-based) may help when food intake is inadequate, particularly after a resistance training session. Protein targets should be individualised in patients with chronic kidney disease — those with eGFR below 30 need nephrology input.

What medications can worsen frailty or sarcopenia?

Several drug classes are significant contributors to frailty progression and fall risk. Sedatives and benzodiazepines impair alertness, coordination, and muscle function. Anticholinergic medications cause cognitive dulling, sedation, and constipation. Antihypertensive over-treatment causes postural hypotension and falls. Sulfonylureas risk hypoglycaemia with associated falls. Corticosteroids at high doses and long duration are directly catabolic to muscle. GLP-1 receptor agonists and dual agonists (semaglutide, tirzepatide) cause weight loss that includes approximately 25–40% lean tissue — a meaningful concern in already-sarcopenic older adults; when used in this group, they should be paired with resistance training and adequate protein intake. Regular polypharmacy review using STOPP/START 2023 criteria and a Home Medicines Review (HMR, MBS item 900) is a key component of frailty management.

Frailty and sarcopenia

Frailty and sarcopenia: identifying and reversing decline in older adults

By Dr HB Lo, FACRRM Reviewed 13 June 2026 9 min read

Frailty is reduced physiological reserve in which minor stressors cause disproportionate decline; sarcopenia is the underlying loss of muscle strength and mass. Together they affect approximately 15% of community-dwelling Australians aged 65 and over. The pre-frail stage — meeting one or two Fried criteria — is the highest-yield intervention window.

Progressive resistance training and adequate protein intake are the most supported strategies. The Clinical Frailty Scale is the practical screening tool, embedded in the 75+ Health Assessment. Polypharmacy review, vitamin D correction, GPCCMP allied health, and advance care planning complete the framework.

Frailty is not an inevitable destination of ageing — it is a measurable clinical state with identifiable causes and a meaningful window for reversal, particularly at the pre-frail stage. Yet it frequently goes unrecognised in Australian general practice until a crisis — a fall, a hospitalisation, an acute infection producing disproportionate confusion — makes it unmissable.

The challenge is that frailty accumulates quietly. Each missed step on the physiotherapy referral, each month of inadequate protein intake, each inappropriately continued sedative adds to the deficit. By the time grip strength is obviously low or walking speed is clearly slow, the person has often lost months of opportunity to reverse course.

A. Core clinical — the AU general-practice framework

Definitions

Frailty is a clinical syndrome of decreased physiological reserve and increased vulnerability to stressors — minor illnesses, medications, or procedural interventions — that produce disproportionate decompensation. Two operational models dominate:

Fried Frailty Phenotype (Fried et al., J Gerontol 2001) — five physical criteria: unintentional weight loss ≥4.5 kg/year, exhaustion (self-reported), weakness (low grip strength), slowness (gait speed below 0.8 m/s), low physical activity. 0 = robust; 1–2 = pre-frail; ≥3 = frail.
Rockwood Clinical Frailty Scale (CMAJ 2005) — nine-point pictorial scale from very fit (1) to terminally ill (9), completed by clinical impression. CFS ≥5 = mild-to-moderate frailty.

Sarcopenia — progressive, generalised skeletal muscle disorder; EWGSOP2 2019 (Cruz-Jentoft et al., Age & Ageing) defines:

Probable: grip strength below 27 kg (men) / below 16 kg (women), or chair-rise >15 seconds for 5 stands
Confirmed: probable + low muscle quantity on DXA (appendicular skeletal muscle mass below 7.0 kg/m² men / below 5.5 kg/m² women) or bioimpedance
Severe: confirmed + low physical performance (gait speed below 0.8 m/s, SPPB ≤8, TUG >20 seconds)

Pre-frailty (Fried score 1–2) is the highest-yield intervention window — exercise and nutrition can return a pre-frail person to robust. Once frailty is established (score ≥3), the goal shifts to stabilisation, prevention of acceleration, and function preservation.

Epidemiology in Australia

The ANZSGM estimates frailty prevalence at approximately 10–15% of community-dwelling adults aged 65 and over, and 40–50% in residential aged care. Pre-frailty affects a further 40–50% of community-dwelling older adults — a large group in whom prevention is actionable.

For Aboriginal and Torres Strait Islander peoples, frailty presents approximately a decade earlier. The RACGP Silver Book and ANZSGM recommend applying 75+ assessment thresholds from age 55 in ATSI populations, and using the ATSI Health Assessment (MBS item 715) for systematic case finding.

Screening and assessment

Clinical Frailty Scale (CFS) — the most practical general-practice tool. Embed in the annual 75+ Health Assessment (MBS item 705) alongside functional, falls, cognition, medication, nutrition, and social review. Also apply at post-acute discharge and opportunistically in recurrent fallers, those on five or more medications, or those with unintentional weight loss.

Fried Frailty Phenotype — more precise; requires a grip dynamometer and timed walk. Appropriate in clinics with equipment or for research-grade assessment.

Timed Up and Go (TUG) — patient stands from a chair, walks 3 metres, returns, and sits. Time >12 seconds = increased fall risk; >20 seconds = severe impairment.

Short Physical Performance Battery (SPPB) — balance tests, 4-metre gait speed, and 5-chair-rise; score ≤8 indicates poor physical performance.

Grip strength dynamometer — single most predictive sarcopenia measure; low-cost, reproducible.

MNA-SF (Mini Nutritional Assessment — Short Form) — preferred nutrition screen in older adults.

Investigations

Blood tests to identify reversible contributors: FBC, UEC, calcium, magnesium, phosphate, LFTs, TSH, ferritin, B12, folate, 25-OH-vitamin D, HbA1c, fasting lipids, CRP, albumin, urinary albumin/creatinine ratio. In men with suspected sarcopenia, add fasting morning total testosterone and SHBG (to assess hypogonadism as a reversible driver).

DXA body composition (MBS item 12306) when sarcopenia confirmation is needed and concurrent osteoporosis assessment is indicated — a practical combined use.

B. Evidence appraisal — what the key trials established

Progressive resistance training

A Cochrane meta-analysis by Liu and Latham (2009) across 121 randomised controlled trials found that progressive resistance training in older adults significantly improved strength, gait speed, and physical function. The average effect on walking speed and chair-rise capacity was clinically meaningful. Effect sizes were larger when programmes were supervised, progressive (gradually increasing load), and sustained for 8–12 weeks or longer.

Combined exercise — the LIFE trial

The LIFE trial (Pahor et al., JAMA 2014) randomised 1,635 pre-frail and frail community-dwelling older adults to a structured physical activity programme (aerobic + resistance + balance) versus a health education control. The physical activity group had significantly lower rates of major mobility disability — defined as the inability to walk 400 metres unassisted — over a median follow-up of 2.6 years. This is the outcome that matters most to patients and their families: maintaining the ability to walk and live independently.

Protein intake — PROT-AGE

The PROT-AGE consensus (Bauer et al., JAMDA 2013) — an international expert group — reviewed evidence for protein requirements in older adults and recommended 1.0–1.2 g/kg/day for healthy older adults and 1.2–1.5 g/kg/day during recovery from acute illness or with chronic disease. Distribution matters — 25–30 g of protein per meal optimises the anabolic signal at muscle protein synthesis level.

C. Pharmacological considerations and polypharmacy

Vitamin D

Correct deficiency (25-OH-vitamin D below 50 nmol/L) with 1,000–2,000 IU daily cholecalciferol, per Healthy Bones Australia. Do not supplement adults with adequate vitamin D levels — a USPSTF 2018 review (JAMA) found no fall or fracture benefit in vitamin D-replete adults, and an annual high-dose bolus may increase fall risk. Cholecalciferol is available on the general schedule and over the counter.

Testosterone replacement

Reserve for men with biochemically confirmed hypogonadism: fasting morning total testosterone below 8 nmol/L on two separate occasions with LH/FSH consistent with primary or secondary hypogonadism. PBS Authority Required criteria apply. The TRAVERSE trial (Lincoff et al., NEJM 2023) found no increase in cardiovascular events compared with placebo in middle-aged and older men with hypogonadism, reassuring on cardiovascular safety. Testosterone is not appropriate for men with age-related “low-normal” testosterone in the absence of biochemical confirmation and symptoms.

GLP-1 receptor agonists in older adults with obesity

Semaglutide, tirzepatide, and related agents drive meaningful weight loss but approximately 25–40% of that weight loss is lean tissue, not fat. In older adults who may already be sarcopenic, this requires active mitigation: concurrent progressive resistance training, protein intake ≥1.2 g/kg/day, and dietitian involvement. Reassess indication, BMI floor, and weight-loss target every six months with the older patient.

Polypharmacy review — high yield in frailty

Medicines contributing to frailty acceleration include: sedatives (benzodiazepines, Z-drugs), anticholinergics (bladder agents, older antihistamines, TCAs), antihypertensives causing postural hypotension, and sulfonylureas causing hypoglycaemia. STOPP/START 2023 criteria provide a structured review framework. A Home Medicines Review (HMR, MBS item 900) by a community pharmacist is high-value and should be arranged for frail patients on five or more medications.

D. Australian operations

MBS items

GP consultations: 23, 36, 44; home visits 24, 37, 47 for housebound patients
75+ Health Assessment: item 705 — annual; the workhorse item for frailty case-finding
ATSI Health Assessment: item 715
GPCCMP preparation and review: items 965/967 — frailty with any chronic disease qualifies; minimum 18-month allied health continuity recommended
Home Medicines Review: item 900
RMMR (residential aged care): item 903
Exercise physiologist under GPCCMP: item 10953
Dietitian: item 10954
Occupational therapist: item 10958
Physiotherapist: item 10960
Podiatry: item 10962
Mental Health Care Plan (late-life depression): items 2715/2717
DXA body composition + bone density: item 12306
Geriatrician (initial/subsequent): items 110/116

My Aged Care

My Aged Care is the gateway to funded home support. Frail and pre-frail older adults may access:

Commonwealth Home Support Programme (CHSP) — entry-level home services, including the Reablement/Restorative Care Programme targeting reversal of mild functional decline
Home Care Package (Level 1–4) — for more complex needs, via ACAT assessment
Residential aged care — via ACAT for those who can no longer remain at home safely

Living Longer Living Stronger — COTA Australia runs group-based progressive resistance training programmes in community settings nationally; accessible, affordable, and evidence-aligned.

DVA

Gold and White Card holders can access allied health (physiotherapy, exercise physiology, dietitian, OT, podiatry), equipment, home modifications, and residential care through DVA funding.

E. Special populations

Hospitalised older adults. Hospitalisation accelerates frailty — immobility, sleep disruption, catheterisation, and sedation all contribute to post-hospital deconditioning. Early mobilisation, avoidance of unnecessary devices (indwelling urinary catheters, restraints), prevention of delirium, and early allied health involvement are the practical priorities. Discharge planning should include a community exercise referral and nutrition review.

Residential aged care residents. Frailty prevalence 40–50%; multiple comorbidities; polypharmacy. The GP’s role includes regular medication review (RMMR item 903), functional monitoring, delirium prevention, advance care planning, and coordination with the RN and allied health team.

Cognitively impaired older adults. Frailty and dementia frequently coexist and accelerate each other. Frailty management goals shift toward maintaining quality of life and function rather than strength targets. The CFS is validated in this group. ACP discussions should include advance care directives and enduring guardianship documentation — Advance Care Planning Australia provides state-specific resources.

Sarcopenic obesity. Low muscle mass combined with excess adiposity — increasingly common in older adults with metabolic syndrome. Underrecognised because BMI appears normal or elevated, masking muscle deficit. DXA or bioimpedance reveals the dual pathology. Management combines PRT and adequate protein with nutritional quality improvements; aggressive caloric restriction alone worsens sarcopenia.

When to escalate

Refer to a geriatrician when:

CFS ≥6 (moderate-to-severe frailty) or rapid unexplained functional decline
Complex multimorbidity making management decisions difficult
Formal Comprehensive Geriatric Assessment needed for surgical risk stratification
Cognitive impairment complicating frailty management

Refer to the appropriate specialist for:

Driving fitness assessment (Austroads 2022 framework — GP-initiated review triggered by CFS progression or falls)
Capacity assessment when medical, financial, or legal decision-making capacity is uncertain
Elder abuse concerns — report per state framework; Compass provides national guidance

What this article is and is not

This is general health information based on the RACGP Silver Book, ANZSGM position statements, EWGSOP2 sarcopenia consensus, PROT-AGE recommendations, and the LIFE and Cochrane resistance training trial evidence. It does not constitute personal medical advice. Frailty and sarcopenia management is highly individualised — exercise prescription, protein targets, medication review, and care planning decisions are made with the treating GP, exercise physiologist, dietitian, and specialist team who know the individual’s full clinical picture, goals, and living situation.

For patient-level information: My Aged Care, HealthDirect — Frailty, Better Health Channel — Sarcopenia, and Living Longer Living Stronger via COTA.

Sources cited

Frequently asked questions

What is the difference between frailty and just being old?

Not all older adults are frail — many people in their eighties and nineties maintain robust physical function and resilience. Frailty is a clinical syndrome, not a synonym for ageing. It is defined by measurable criteria: unintentional weight loss, exhaustion, weakness (low grip strength), slowness (reduced walking speed), and low physical activity. A person who meets three or more of these criteria is frail; those with one or two are pre-frail and at the highest-yield intervention point. The distinction matters practically because frail patients decompensate from minor stressors that healthy older adults would tolerate easily — for example, a urinary tract infection causing acute confusion and a fall, rather than just a few days of discomfort. Identifying frailty early allows targeted intervention before this point is reached.
What is the Clinical Frailty Scale and how is it used?

The Clinical Frailty Scale (CFS), developed by Rockwood and colleagues and published in CMAJ 2005, is a nine-point pictorial scale ranging from 1 (very fit) to 9 (terminally ill). It is completed by clinical impression — no equipment is needed. A score of 5 or above indicates mild-to-moderate frailty and is a clinical inflection point for proactive action: medication review, allied health referral, advance care planning discussion, and monitoring for deconditioning. The CFS is the most practical general-practice frailty screening tool and is embedded in the annual 75+ Health Assessment (MBS item 705). It is also used for surgical risk stratification and decisions about the intensity of hospital-based care. For Aboriginal and Torres Strait Islander patients, frailty appears earlier — apply 75+ assessment thresholds from age 55.
What is sarcopenia and how is it diagnosed?

Sarcopenia is the progressive, generalised loss of skeletal muscle strength and mass that occurs with ageing, accelerated by inactivity, malnutrition, and chronic disease. The EWGSOP2 consensus (Cruz-Jentoft, Age & Ageing 2019) defines it in stages: probable sarcopenia when grip strength is below 27 kg in men or 16 kg in women (or chair-rise time exceeds 15 seconds for five stands); confirmed sarcopenia when low muscle quantity is also found on DXA or bioimpedance; and severe sarcopenia when physical performance is also reduced (walking speed below 0.8 m/s, SPPB score ≤8, or Timed Up and Go above 20 seconds). In Australian general practice, a grip strength dynamometer and chair-rise test are the most accessible bedside assessments. DXA adds body composition data — useful when osteoporosis assessment is also indicated.
What exercises are most effective for frailty and sarcopenia?

Progressive resistance training (PRT) — working against gradually increasing loads — is the single most evidence-supported intervention. A Cochrane review (Liu and Latham 2009) across 121 trials found PRT improves strength, gait speed, chair-rise performance, and functional capacity in older adults. The LIFE trial (Pahor et al., JAMA 2014) found that a combined programme of resistance, balance, and aerobic exercise reduced major mobility disability in pre-frail and frail community-dwelling older adults. The practical recommendation is two to three sessions per week targeting major lower-limb muscle groups (squat, leg press, knee extension, calf raise) plus upper limb, with intensity progressed over eight to twelve weeks. Exercise physiologist referral under GPCCMP (MBS item 10953) provides supervised prescription. Tai chi adds balance benefit and fall risk reduction. A short walk is not enough — intensity and progressive loading are essential for muscle preservation.
How much protein do older adults need to preserve muscle?

More than previously recognised. The PROT-AGE consensus (Bauer et al., JAMDA 2013) recommends 1.0–1.2 g of protein per kilogram of body weight per day for healthy older adults, and 1.2–1.5 g/kg/day during recovery from illness, surgery, or acute deconditioning. Distribution across meals matters — 25–30 g of protein per meal optimises muscle protein synthesis by providing a sufficient leucine stimulus. A common failure is the 'tea and toast' dietary pattern, where most calories come from carbohydrates and total daily protein is well below requirements. Good protein sources include meat, fish, eggs, dairy, legumes, and soy. Protein supplements (whey-based) may help when food intake is inadequate, particularly after a resistance training session. Protein targets should be individualised in patients with chronic kidney disease — those with eGFR below 30 need nephrology input.
What medications can worsen frailty or sarcopenia?

Several drug classes are significant contributors to frailty progression and fall risk. Sedatives and benzodiazepines impair alertness, coordination, and muscle function. Anticholinergic medications cause cognitive dulling, sedation, and constipation. Antihypertensive over-treatment causes postural hypotension and falls. Sulfonylureas risk hypoglycaemia with associated falls. Corticosteroids at high doses and long duration are directly catabolic to muscle. GLP-1 receptor agonists and dual agonists (semaglutide, tirzepatide) cause weight loss that includes approximately 25–40% lean tissue — a meaningful concern in already-sarcopenic older adults; when used in this group, they should be paired with resistance training and adequate protein intake. Regular polypharmacy review using STOPP/START 2023 criteria and a Home Medicines Review (HMR, MBS item 900) is a key component of frailty management.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.